AbbVie – Page 2

AbbVie Expands Immunology Pipeline with $200M Acquisition of Nimble Therapeutics

4 months ago talkbio0Tagged AbbVie, Autoimmune Diseases, IL23R gene, Immunology, Inhibitor, Nimble, Peptides, Psoriasis

AbbVie, Nimble Therapeutics, Immunology, Psoriasis, Autoimmune Diseases, IL23R Inhibitor, Peptide Therapeutics

Alector Cuts 17% of Workforce Following Failure of AbbVie-Partnered Alzheimer’s Drug in Phase 2 Trial

5 months ago talkbio0Tagged AbbVie, Alector, Alzheimer 's disease, Failure (biologic function), Industry, Phase 2 trial

Alector, layoffs, AbbVie, Alzheimer’s disease, phase 2 trial failure, biotech industry

AbbVie’s Schizophrenia Drug Fails in Phase II Trials, Casting Doubt on Neuroscience Strategy

5 months ago talkbio0Tagged AbbVie, Cerevel, Drug Industry, Emraclidine, Neuroscience discipline, Phase 2 Clinical Trials, Schizophrenia

AbbVie, schizophrenia, emraclidine, Phase II trials, Cerevel Therapeutics, neuroscience strategy, pharmaceutical industry

GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others

5 months ago talkbio0Tagged AbbVie, AppTec, Bio, Biotechnology, Drug Industry, lobbying, Pfizer, SmithKline Beecham, Takeda, TNFRSF19 gene, UCB, WuXi

GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying

AbbVie and EvolveImmune Therapeutics Collaborate on Next-Generation Cancer Biotherapeutics Using T-Cell Engager Technology

6 months ago talkbio0Tagged AbbVie, Biological Factors, EvolveImmune, Immunotherapy, Next-Generation Cancer, Oncology Collaboration, T-Cell Engager Technology, Tumor cells, malignant

AbbVie, EvolveImmune Therapeutics, T-Cell Engager Technology, Next-Generation Cancer Biotherapeutics, Oncology Collaboration, Multispecific Biologics, Cancer Cell Resistance, Immunotherapies

Skyrizi Surpasses Humira as AbbVie’s Top-Selling Drug

6 months ago talkbio0Tagged AbbVie, Arthritis, Psoriatic, Crohn 's disease, Dental Plaque, Humira, Immunology, Psoriasis, Skyrizi

Skyrizi, Humira, AbbVie, revenue leader, immunology, plaque psoriasis, psoriatic arthritis, Crohn’s disease

AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics

6 months ago talkbio0Tagged AbbVie, ALIA-1758, Aliada, Alzheimer 's disease, anti-amyloid, asset, Blood - brain barrier anatomy, CNS disorder, pharmaceutical acquisition, Study models, Technology

AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition